These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 21507733

  • 21. Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.
    van Koningsbruggen-Rietschel S, Heuer HE, Merkel N, Posselt HG, Staab D, Sieder C, Ziegler J, Krippner F, Rietschel E.
    J Antimicrob Chemother; 2016 Mar; 71(3):711-7. PubMed ID: 26626719
    [Abstract] [Full Text] [Related]

  • 22. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre.
    Manno G, Cruciani M, Romano L, Scapolan S, Mentasti M, Lorini R, Minicucci L.
    Int J Antimicrob Agents; 2005 Mar; 25(3):193-7. PubMed ID: 15737511
    [Abstract] [Full Text] [Related]

  • 23. Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis.
    Howlin RP, Cathie K, Hall-Stoodley L, Cornelius V, Duignan C, Allan RN, Fernandez BO, Barraud N, Bruce KD, Jefferies J, Kelso M, Kjelleberg S, Rice SA, Rogers GB, Pink S, Smith C, Sukhtankar PS, Salib R, Legg J, Carroll M, Daniels T, Feelisch M, Stoodley P, Clarke SC, Connett G, Faust SN, Webb JS.
    Mol Ther; 2017 Sep 06; 25(9):2104-2116. PubMed ID: 28750737
    [Abstract] [Full Text] [Related]

  • 24. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D, Stableforth D.
    Drugs; 2000 Nov 06; 60(5):1053-64. PubMed ID: 11129122
    [Abstract] [Full Text] [Related]

  • 25. Population Pharmacokinetics of Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis.
    Wang X, Koehne-Voss S, Anumolu SS, Yu J.
    J Pharm Sci; 2017 Nov 06; 106(11):3402-3409. PubMed ID: 28634121
    [Abstract] [Full Text] [Related]

  • 26. Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment.
    Valenza G, Radike K, Schoen C, Horn S, Oesterlein A, Frosch M, Abele-Horn M, Hebestreit H.
    Scand J Infect Dis; 2010 Dec 06; 42(11-12):885-9. PubMed ID: 20735333
    [Abstract] [Full Text] [Related]

  • 27. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis.
    Moreno-Sastre M, Pastor M, Esquisabel A, Sans E, Viñas M, Fleischer A, Palomino E, Bachiller D, Pedraz JL.
    Int J Pharm; 2016 Feb 10; 498(1-2):263-73. PubMed ID: 26705155
    [Abstract] [Full Text] [Related]

  • 28. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
    Cheer SM, Waugh J, Noble S.
    Drugs; 2003 Feb 10; 63(22):2501-20. PubMed ID: 14609360
    [Abstract] [Full Text] [Related]

  • 29. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
    Ciofu O, Giwercman B, Pedersen SS, Høiby N.
    APMIS; 1994 Sep 10; 102(9):674-80. PubMed ID: 7946270
    [Abstract] [Full Text] [Related]

  • 30. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M, Nazareth D, Walshaw M.
    J Aerosol Med Pulm Drug Deliv; 2014 Aug 10; 27(4):299-305. PubMed ID: 24219814
    [Abstract] [Full Text] [Related]

  • 31. Moxalactam-tobramycin-resistant Pseudomonas aeruginosa isolates in patients with cystic fibrosis.
    Fitzpatrick SB, Rosenstein BJ.
    Clin Pediatr (Phila); 1983 Sep 10; 22(9):628-30. PubMed ID: 6224623
    [Abstract] [Full Text] [Related]

  • 32. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
    Sawicki GS, Signorovitch JE, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L.
    Pediatr Pulmonol; 2012 Jan 10; 47(1):44-52. PubMed ID: 21815282
    [Abstract] [Full Text] [Related]

  • 33. What have we learned about early treatment of Pseudomonas aeruginosa infection in infants and children with cystic fibrosis?
    Saiman L, Cohen MB.
    Arch Pediatr Adolesc Med; 2011 Sep 10; 165(9):867-8. PubMed ID: 21893653
    [No Abstract] [Full Text] [Related]

  • 34. Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis.
    Antoniu S.
    Expert Rev Anti Infect Ther; 2015 Jul 10; 13(7):897-905. PubMed ID: 25921312
    [Abstract] [Full Text] [Related]

  • 35. TOBI Podhaler for cystic fibrosis patients with Pseudomonas aeruginosa.
    Farinde A.
    Nurse Pract; 2015 Jul 15; 40(7):16-7. PubMed ID: 26080292
    [No Abstract] [Full Text] [Related]

  • 36. Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis.
    Griese M, Müller I, Reinhardt D.
    Eur J Med Res; 2002 Feb 21; 7(2):79-80. PubMed ID: 11891148
    [Abstract] [Full Text] [Related]

  • 37. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
    Canis F, Trivier D, Vic P, Ategbo S, Turck D, Husson MO.
    Pathol Biol (Paris); 1998 Jun 21; 46(6):449-51. PubMed ID: 9769880
    [Abstract] [Full Text] [Related]

  • 38. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
    Lenoir G, Antypkin YG, Miano A, Moretti P, Zanda M, Varoli G, Monici Preti PA, Aryayev NL.
    Paediatr Drugs; 2007 Jun 21; 9 Suppl 1():11-20. PubMed ID: 17536871
    [Abstract] [Full Text] [Related]

  • 39. Early Pseudomonas aeruginosa colonisation in cystic fibrosis patients.
    Taccetti G, Repetto T, Procopio E, Farina S, Campana S.
    Lancet; 2002 Feb 16; 359(9306):625-6. PubMed ID: 11867138
    [No Abstract] [Full Text] [Related]

  • 40. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Hansen C, Skov M.
    Ther Adv Respir Dis; 2015 Feb 16; 9(1):16-21. PubMed ID: 25471692
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.